YNL144C Antibody

What is YNL144C and why is it significant for antibody-based research?

YNL144C is a systematic designation for a yeast gene in Saccharomyces cerevisiae that has been identified in genetic studies. The protein encoded by this gene appears to have a fold change of approximately 2.51-2.16 in certain experimental conditions, suggesting it may play a role in cellular responses to environmental conditions . Antibodies targeting this protein are valuable for studying its expression, localization, and interactions in yeast cells. The significance lies in understanding fundamental cellular processes in yeast, which often serve as model organisms for eukaryotic cell biology.

What basic validation steps should be performed with a new YNL144C antibody?

When working with a new YNL144C antibody, researchers should perform the following validation steps:

• Western blot analysis using wild-type yeast extracts versus YNL144C knockout strains

• Immunoprecipitation followed by mass spectrometry confirmation

• Immunofluorescence microscopy to confirm expected subcellular localization patterns

• Testing antibody specificity across different experimental conditions

• Cross-reactivity assessment with related yeast proteins

These validation approaches can be performed using standard immunoblot analysis protocols similar to those described for other yeast proteins . Typically, a dilution series (e.g., 1:1000 to 1:5000) should be tested to determine optimal antibody concentration.

How should researchers interpret unexpected banding patterns when using YNL144C antibodies in Western blots?

Unexpected banding patterns in Western blots may result from:

When encountering unexpected banding patterns, researchers should first verify antibody specificity using appropriate controls, including YNL144C deletion strains. For reproducible results, preparation of yeast extracts should follow standardized protocols similar to those used for immunoblot analysis in yeast studies .

What are the optimal fixation and permeabilization conditions for immunofluorescence microscopy with YNL144C antibodies?

For optimal immunofluorescence microscopy with YNL144C antibodies:

• Fix yeast cells with 3.7% formaldehyde for 30 minutes at room temperature

• Wash three times with phosphate buffer containing 1.2M sorbitol

• Digest cell walls with zymolyase (100 μg/ml) for 20-30 minutes

• Permeabilize with 0.1% Triton X-100 for 5 minutes

• Block with 3% BSA for 1 hour before antibody incubation

This approach preserves cellular structures while allowing antibody access to intracellular antigens. When optimizing these conditions, researchers should consider that membrane-associated proteins may require gentler permeabilization conditions to preserve localization patterns. Similar approaches have been used successfully for visualizing yeast cellular components in studies of fungal morphogenesis .

How can YNL144C antibodies be used to study protein-protein interactions in yeast?

YNL144C antibodies can be employed in several approaches to study protein-protein interactions:

• Co-immunoprecipitation (Co-IP): Use YNL144C antibodies conjugated to magnetic or agarose beads to pull down the protein and its interacting partners from yeast lysates, followed by mass spectrometry analysis.

• Proximity Ligation Assay (PLA): Combine YNL144C antibodies with antibodies against suspected interaction partners to visualize protein interactions in situ when proteins are within 40nm of each other.

• Chromatin Immunoprecipitation (ChIP): If YNL144C has DNA-binding properties, ChIP using specific antibodies can identify genomic binding sites.

• Two-hybrid validation: Following identification of potential interactors through yeast two-hybrid screening , antibodies can validate these interactions in native contexts.

The choice of method depends on the research question, with Co-IP being most suitable for stable interactions and PLA for transient or context-dependent interactions.

What are the considerations for using YNL144C antibodies in FACS-based experiments?

When using YNL144C antibodies for flow cytometry applications:

• Cell preparation: Optimize fixation and permeabilization protocols specifically for flow cytometry (typically milder than for microscopy).

• Antibody titration: Perform careful titration experiments to determine optimal antibody concentration that maximizes specific signal while minimizing background.

• Controls: Include isotype controls, secondary-only controls, and YNL144C deletion strains.

• Fluorophore selection: Choose fluorophores with spectral properties compatible with available laser/filter combinations and consider potential autofluorescence of yeast cells.

• Live cell considerations: For live cell applications, verify that antibody binding doesn't alter cell viability or the protein's function.

These considerations are particularly important when studying dynamic processes such as reactive oxygen species (ROS) detection or programmed cell death, where proper controls must be implemented to distinguish specific antibody signals from cellular autofluorescence .

How can researchers develop nanobodies against YNL144C for advanced applications?

Developing nanobodies against YNL144C would follow these methodological steps:

• Immunization: Immunize alpacas or llamas with purified YNL144C protein to generate heavy-chain only antibodies.

• Library construction: After immune response confirmation, isolate peripheral blood lymphocytes, extract RNA, and generate cDNA libraries of variable domains.

• Selection: Perform phage display or yeast display to select high-affinity binders to YNL144C.

• Validation: Test selected nanobodies for specificity using techniques like ELISA, SPR, and immunoprecipitation with yeast extracts.

• Characterization: Determine binding kinetics, epitope mapping, and test functionality in relevant assays.

Nanobodies offer advantages over conventional antibodies for certain applications due to their smaller size (approximately 15 kDa), stability, and ability to recognize hidden epitopes. Similar approaches have proven successful for developing nanobodies against other targets, such as PRL-3 in cancer research, where nanobodies could identify targets within cells and attach to active sites of proteins .

What strategies can address cross-reactivity when YNL144C antibodies recognize homologous proteins in Candida albicans?

When cross-reactivity with Candida albicans homologs occurs:

• Epitope mapping: Identify the specific epitope recognized by the antibody and compare sequence conservation across species.

• Absorption protocols: Pre-incubate antibodies with recombinant protein from cross-reactive species to deplete non-specific binders.

• Competitive blocking: Use peptides corresponding to divergent regions to specifically block cross-reactive epitopes.

• Genetic validation: Use CRISPR-edited strains of both organisms lacking the target protein to confirm specificity.

• Species-specific antibody development: Design antibodies against non-conserved regions or develop monoclonal antibodies with higher specificity.

This approach is particularly relevant when studying fungal pathogens like Candida albicans, which share homologous proteins with the model organism S. cerevisiae. Understanding these cross-reactions is critical when studying conserved pathways between commensal and pathogenic fungi .

How can researchers integrate phospho-specific YNL144C antibodies into studies of signaling pathways?

Phospho-specific YNL144C antibodies can be integrated into signaling research through:

• Phosphorylation site identification: First, identify potential phosphorylation sites in YNL144C using mass spectrometry and bioinformatics prediction tools.

• Phospho-specific antibody generation: Develop antibodies that specifically recognize phosphorylated forms at these sites.

• Validation in vitro: Confirm specificity using phosphatase-treated samples and phosphomimetic mutants.

• Signaling dynamics: Use these antibodies to track temporal changes in YNL144C phosphorylation in response to various stimuli.

• Pathway mapping: Combine with inhibitors of specific kinases to establish pathway connections.

• Quantitative analysis: Employ phospho-specific antibodies in quantitative immunoblotting or ELISA to measure phosphorylation levels precisely.

This approach is particularly valuable for studying kinase-substrate relationships, such as those involving PKA/Tpk1-3 or other signaling pathways in yeast that may regulate YNL144C function through post-translational modifications .

What are the recommended protocols for achieving reproducible immunoprecipitation of YNL144C from yeast lysates?

For reproducible immunoprecipitation of YNL144C:

• Cell disruption: Use glass bead lysis in buffer containing 50mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 10% glycerol, with freshly added protease inhibitors.

• Antibody coupling: Pre-couple YNL144C antibodies to Protein G magnetic beads (5μg antibody per 50μl beads) using dimethyl pimelimidate for covalent attachment.

• Pre-clearing: Pre-clear lysates with uncoupled beads for 1 hour at 4°C to reduce non-specific binding.

• Immunoprecipitation: Incubate pre-cleared lysates with antibody-coupled beads overnight at 4°C with gentle rotation.

• Washing: Wash beads 5 times with lysis buffer containing gradually decreasing salt concentrations.

• Elution: Elute bound proteins with 0.1M glycine pH 2.5 or by boiling in SDS sample buffer.

• Controls: Always include a non-specific IgG control and, when possible, a YNL144C deletion strain.

This protocol incorporates best practices from yeast extract preparation for immunoblot analysis while addressing specific challenges in immunoprecipitation experiments .

How should researchers quantitatively analyze YNL144C expression levels across different experimental conditions?

For quantitative analysis of YNL144C expression:

• Sample preparation standardization:

  • Use consistent cell numbers or OD measurements

  • Extract proteins under identical conditions

  • Include spike-in controls for normalization

• Western blot quantification:

  • Run standard curves of recombinant YNL144C

  • Use fluorescent secondary antibodies for wider linear range

  • Analyze with software like ImageJ using appropriate background correction

• qPCR for transcript analysis:

  • Design primers specific to YNL144C

  • Validate primer efficiency with standard curves

  • Use appropriate reference genes (ACT1, TDH3)

• Data normalization approaches:

• Statistical analysis:

  • Perform at least three biological replicates

  • Apply appropriate statistical tests (t-test, ANOVA)

  • Report fold-changes with error bars

These quantification approaches mirror methodologies used in DNA microarray analysis and can be applied to study YNL144C expression under various conditions .

What controls are essential when using YNL144C antibodies to study protein function in conditional mutants?

When using YNL144C antibodies with conditional mutants, essential controls include:

• Genetic controls:

  • Wild-type strain processed identically

  • Complete YNL144C deletion strain as negative control

  • Complemented strain to confirm phenotype rescue

  • Strains with mutations in interacting proteins

• Expression controls:

  • Verification of conditional expression/depletion by Western blot

  • Time-course of protein levels following condition shift

  • Measurement of transcript levels by qPCR

• Functionality controls:

  • Known downstream effects of YNL144C function

  • Subcellular localization under permissive/restrictive conditions

  • Interaction profile changes using co-immunoprecipitation

• Technical controls:

  • Secondary antibody-only controls

  • Non-specific IgG controls

  • Loading controls that remain stable under test conditions

These controls are particularly important when working with tetracycline-regulated promoters or other conditional systems that allow for the depletion of essential proteins in yeast, as described in protocols for the insertion of tetO7 promoter and depletion of proteins like Pkh .

How can researchers resolve contradictory results between YNL144C antibody-based detection and genetic reporter systems?

When antibody-based detection contradicts genetic reporter results:

• Verify antibody specificity:

  • Test antibody against YNL144C deletion strains

  • Perform epitope mapping to confirm target recognition

  • Check for post-translational modifications that might affect antibody binding

• Evaluate reporter system:

  • Confirm proper integration of reporter constructs

  • Verify transcriptional and translational integrity

  • Test reporter functionality with known controls

• Consider temporal dynamics:

  • Protein levels (detected by antibodies) may lag behind transcription (reporter systems)

  • Perform time-course experiments to capture both signals

• Assess technical factors:

  • Different sensitivities between detection methods

  • Potential interference from experimental conditions

  • Subcellular compartmentalization affecting detection

• Reconciliation approaches:

  • Use orthogonal methods (e.g., mass spectrometry)

  • Develop single-cell approaches to correlate both measurements

  • Consider mathematical modeling to explain differences

This systematic troubleshooting approach helps reconcile apparently contradictory results that may arise from different detection methodologies .

What are the best strategies for integrating YNL144C antibody-based studies with high-throughput screening approaches?

Integrating YNL144C antibody studies with high-throughput screening:

• Antibody validation for high-throughput applications:

  • Confirm specificity and sensitivity in plate-based formats

  • Establish Z-factor for assay quality assessment

  • Develop automated imaging analysis workflows if using microscopy

• Screening design considerations:

  • Use YNL144C antibodies in reverse-phase protein arrays

  • Develop ELISA-based quantification for screening hit validation

  • Consider multiplex approaches with other relevant targets

• Data integration framework:

  • Correlate antibody-based readouts with phenotypic data

  • Implement machine learning for pattern recognition across datasets

  • Develop visualization tools for multi-parameter data analysis

• Validation pipeline for hits:

  • Secondary screening with orthogonal antibody-based methods

  • Genetic validation of top hits

  • Dose-response confirmation of effects on YNL144C

This integrated approach leverages the specificity of antibody-based detection while enabling the throughput needed for comprehensive screening campaigns, similar to approaches used in antibody therapeutics development tracking .

How can researchers distinguish between direct and indirect effects on YNL144C using antibody-based approaches?

To distinguish direct from indirect effects:

• Time-course experiments:

  • Monitor YNL144C levels/modifications at short intervals after stimulus

  • Compare timing with other known pathway components

  • Early changes (minutes) often indicate direct effects

• Pharmacological approaches:

  • Use protein synthesis inhibitors to block indirect effects requiring new protein production

  • Apply specific pathway inhibitors to dissect contributions

  • Perform dose-response studies to identify threshold concentrations

• In vitro reconstitution:

  • Test direct interactions with purified components

  • Perform kinase/phosphatase assays with recombinant proteins

  • Use surface plasmon resonance to measure direct binding kinetics

• Proximity-based methods:

  • Employ BioID or APEX2 proximity labeling with YNL144C

  • Use FRET-based sensors to detect direct interactions

  • Apply crosslinking approaches followed by mass spectrometry

• Genetic approaches to complement antibody data:

  • Create specific point mutations that disrupt individual interactions

  • Use rapid protein depletion systems (e.g., auxin-inducible degrons)

  • Perform epistasis analysis with upstream/downstream components

This multi-faceted approach allows researchers to build confidence in determining whether observed effects on YNL144C are direct consequences of experimental interventions or mediated through intermediate factors .

How might therapeutic antibody development approaches inform improved research tools for YNL144C studies?

Therapeutic antibody development strategies that could enhance YNL144C research tools include:

• Antibody engineering approaches:

  • Single-domain antibodies (nanobodies) for improved penetration in yeast cells

  • Site-specific labeling with fluorophores for enhanced imaging

  • Bispecific antibodies to simultaneously detect YNL144C and interaction partners

• Affinity maturation techniques:

  • Phage display for selecting higher-affinity variants

  • Rational design of complementarity-determining regions (CDRs)

  • Computational modeling to predict affinity-enhancing mutations

• Therapeutic antibody screening platforms adaptation:

  • High-throughput antibody characterization workflows

  • Automated epitope binning to generate complementary antibodies

  • Novel formulation strategies for improved antibody stability

• Advanced formats and modifications:

  • Intrabodies optimized for expression within yeast cells

  • pH-sensitive antibodies for compartment-specific detection

  • Antibody fragments with tailored penetration properties

These approaches leverage innovations from therapeutic antibody development, such as those cataloged in the YAbS database, which tracks over 2,900 antibody therapeutics and provides insights into molecular formats and development trends that could be applied to research antibodies .

What are the current limitations of YNL144C antibodies for detecting post-translational modifications, and how might they be overcome?

Current limitations and solutions for detecting YNL144C post-translational modifications:

Limitations:

• Low abundance of modified forms

• Multiple modification sites creating heterogeneous populations

• Transient nature of some modifications

• Cross-reactivity between similar modification patterns

• Context-dependent accessibility of epitopes

Solutions:

Researchers can overcome these limitations by developing highly specific antibodies against individual modifications (phosphorylation, ubiquitination, etc.) and validating them using mutants where modification sites are altered. Emerging technologies from therapeutic antibody development could provide new scaffolds with improved properties for detecting these modifications .

How can computational approaches enhance the development and application of YNL144C antibodies in research?

Computational approaches can enhance YNL144C antibody research in several ways:

• Epitope prediction and antibody design:

  • In silico prediction of immunogenic epitopes on YNL144C

  • Structure-based antibody design targeting specific domains

  • Molecular dynamics simulations to optimize binding interfaces

• Cross-reactivity analysis:

  • Sequence and structural comparison across related proteins

  • Identification of unique regions for specific targeting

  • Prediction of potential off-target binding sites

• Data integration platforms:

  • Systems for correlating antibody-based data with -omics datasets

  • Machine learning to identify patterns in antibody-based screening

  • Network analysis to position YNL144C in relevant pathways

• Imaging and analysis enhancement:

  • Automated image analysis workflows for antibody-based microscopy

  • Deconvolution algorithms for improved signal detection

  • Quantitative analysis pipelines for complex datasets

• Database utilization:

  • Integration with antibody databases like YAbS for method optimization

  • Leveraging successful antibody development strategies from therapeutic areas

  • Mining literature for optimal experimental conditions

These computational approaches can significantly enhance traditional experimental methods, improving both the development of new YNL144C antibodies and the interpretation of data generated using existing ones .